Abstract The mechanistic target of rapamycin (mTOR), a protein kinase, is a central regulator of mammalian metabolism and physiology. Protein mTOR complex 1 (mTORC1) functions as a major sensor for the nutrient, energy, and redox state of a cell and is activated by ras homolog enriched in brain (RHEB1), a GTP-binding protein. Increased activation of mTORC1 pathway has been associated with developmental abnormalities, certain form of epilepsy (tuberous sclerosis), and cancer. Clinically, those mTOR-related disorders are treated with the mTOR inhibitor rapamycin and its rapalogs. Because the effects of chronic interference with mTOR signaling in the aged brain are yet unknown, we used a genetic strategy to interfere with mTORC1 signaling selectively by introducing mutations of Rheb1 into the mouse. We created conventional knockout (Rheb1 +/− ) and gene trap (Rheb1 Δ/+ ) mutant mouse lines. Rheb1-insufficient mice with different combinations of mutant alleles were monitored over a time span of 2 years. The mice did not show any behavioral/neurological changes during the first 18 months of age. However, after aging (> 18 months of age), both the Rheb1 +/− and Rheb1 Δ /− hybrid males developed rare stress-induced seizures, whereas Rheb1 +/− and Rheb1 Δ /− females and Rheb1
Introduction
RHEB1 belongs to a unique family within the Ras superfamily of GTPases (Urano et al. 2000; Li et al. 2004) . Rheb1 was initially identified as a gene whose expression is rapidly induced upon synaptic activity in the rat hippocampus (Yamagata et al. 1994) . Homologs of the Rheb1 gene have been identified in a number of non-mammalian organisms and in mammals including mouse, rat (Ibid), and human (Gromov et al. 1995; Mizuki et al. 1996) ; for review, see (Aspuria and Tamanoi 2004; Heard et al. 2014) . The RHEB1 protein is a direct target of the tuberous sclerosis complex (TSC1/2), and it transmits upstream-signals to regulate mTORC1. TSC1/2 inhibits the mTORC1/S6K/4EBP1 signaling pathway by stimulating GTP hydrolysis of RHEB1 and its functions between TSC1/2 and mTORC1 (Manning and Cantley 2003) . Inactivation of TSC1/2 leads to the activation of the RHEB1/ mTORC1 signaling cascade that is accomplished by phosphorylation of its downstream targets that include p70 S6 kinase (S6 K) and the eukaryotic initiation factor 4E (eIF4E)-binding proteins 1 and 2 (4E-BP1 and 4E-BP2) (Uhlmann et al. 2004; Terauchi et al. 2010 ). RHEB1 together with other members of the TSC1/TSC2/RHEB1/mTORC1 pathway plays an important role in the regulation of cell growth and proliferation, aging, ribosome biogenesis, protein synthesis, actin-cytoskeletal organization, autophagy, and metabolism (Heard et al. 2014) . Abnormal function of TSC1/TSC2/RHEB1/mTORC1 signaling results in different pathologies. In humans, mutations in tumor suppressor genes Tsc1/2 and corresponding inactivation of the TSC1/2 complex leads to inappropriate activation of RHEB1, manifested as tuberous sclerosis complex (TSC) disease (Tee et al. 2003b (Tee et al. , 2003a . The hallmark of TSC is the development of a type of benign tumors called hamartomas found in brain, kidney, lung, and other organs of TS patients (Mizuguchi and Takashima 2001) . The development of hamartoma in brain causes serious neurological manifestations including epilepsy, autism, and mental retardation, affecting 80-90% of the children with TS. To model TSC specifically in the brain, the neuron specific for Tsc1 (Meikle et al. 2007) and an astroglia-specific knock out for Tsc1 (Uhlmann et al. 2002; Zeng et al. 2008) and Tsc2 (Zeng et al. 2011) genes were generated in mouse. Inactivation of any of these genes leads to hyperactivation of the RHEB1/ mTORC1 pathway, causing severe astrocyte proliferation, neuronal disorganization, and corresponding megalocephaly and seizure development. To generate another TSC mouse transgenic model, human Rheb1 was cloned under regulation of the promoter of the nestin gene, selectively expressing RHEB1 in neuronal stem cells of embryonic and adult brains. Several founders overexpressing RHEB1 in brain had hyperplasia of brain's tissues and they died at the age of 3-4 weeks (Tian, Fedorov, unpublished results) . Thus, increased activity of RHEB1/mTORC1 leads to tumor development in different organs of human and other species. On the other hand, the RHEB1 deficiency/insufficiency results in different developmental abnormalities. Gene targeting of Rheb1 in mice leads to embryonic lethality of homozygous embryos around mid-gestation from impaired development of the cardiovascular system (Goorden et al. 2011; Tamai et al. 2013) . Moreover, RHEB1 is vital for adult animals, since tamoxifeninducible Rheb1 knock-out in adult animals results in death of homozygous Rheb1 null mice 18 days after initiating Rheb1 deletion. A conditional knockout of Rheb1 in neural progenitor cells that resulted in a RHEB1expression reduction by > 90% after 2-3 weeks of postnatal development leads to brain growth retardation (50% of weight of w.t. controls) and prominent hypomyelination in all regions of the brain (Zou et al. 2011) .Thus, RHEB1 deficiency as well as serious insufficiency and corresponded reduction of the pathway activity downstream of RHEB1 results in embryonic death and severe morphological malformations of postnatal mice. However, it is almost not known how moderate RHEB1/mTORC1 insufficiency can affect the development and functionality of the brain. In particular, it is interesting because treatment of TSC and other disorders resulting from mTORC1 hyperactivity by the TORC1inhibitor everolimus (rapalog of rapamycin) already results in significant success including reduction of seizure frequency as well as behavioral improvement and tumor regression (French et al. 2016; Franz et al. 2016; Franz 2011; Krueger et al. 2010) . However, to support normal or at least improved health conditions of such patients, it might be necessary to have long-term or lifelong application of mTOR inhibitors. Furthermore, the clinical data indicate that the everolimus treatment results in different side effects including pneumonitis, hyperglycemia, and immunosuppression etc., (for review, Mendus et al. 2015) . Clinical manifestations that occur after mTORC1 inhibitor treatment can potentially be divided into two groups. One group can occur as side effects resulting from a toxicity of mTOR inhibitors. Other manifestations can occur as a result of long-term down-regulation of the mTOR pathway per se. Downregulation of the mTOR pathway without mTOR inhibitors specifically by reduction of RHEB1 expression via gene targeting gives the possibility of better understanding the nature of adverse events related to mTOR inhibition. This is also interesting because RHEB1 is strongly expressed in different regions of the brain responsible for cognition, learning, long short memory, and movement etc. (Tian et al. 2016 ) and its down-regulation can potentially affect these brain functions.
To study the effect of a prolonged moderated reduction in the RHEB1/mTORC1 pathway, we targeted Rheb1 in mice by two different methods. Generation of our Rheb1 Gene Trap (Rheb1 Δ/+ ) mice were described recently (Tian et al. 2016) . By using RHEB1 immunostaining and X-gal staining, we showed that RHEB1 protein expresses in different regions of the brain including the cerebral cortex, subcortical regions (counting hippocampus), cerebellum (particularly in Purkinje cells), and other organs during embryonic and postnatal development. A RHEB1 activation of mTOR is dependent on farnesylation (Hanker et al. 2010) . Therefore, in a second model, we inactivated the Rheb1 gene in embryonic stem cells (ES) cells by targeting the last exon of Rheb1 containing the carboxyl terminus (so-called CSVM motif) that is responsible for the farnesylation and activation of the RHEB1 protein. These RHEB1-insufficient mouse lines were used to study how longterm reduction of RHEB1/mTORC1 signaling can induce behavioral changes and/or neurological disorders.
Results
Generation and phenotype of Rheb1-deficient/ insufficient mice The Rheb1 gene was targeted in ES cells via two strategies. The scheme of the Rheb1 by conventional gene targeting is presented on Fig. 1a- (Fig. 1e) . Living growth-retarded and dead Rheb1 null embryos together accounted for approximately 25% of conceptuses, providing evidence that Rheb1 deletion had no effect on implantation. Histological sections of Rheb1 −/− embryos commonly showed cardiovascular defects similar to those described earlier (Goorden et al. 2011; Tamai et al. 2013 ) (data not shown). Generation of Rheb1 Δ/+ (Rheb1 GT) gene trap mice and the expression pattern of the β-gal reporter gene in their tissues was described recently (Tian et al. 2016 +/− ES cells when a pair of primers was used with at least one of primer binding to exon 8 (Fig. 2b) . qRT-PCR with both pairs of primers showed that Rheb1 Δ/+ ES cells have Rheb1 mRNA levels similar with Rheb1 +/+ ES cells in spite of one Rheb1 allele was Btrapped^. Analysis of Rheb1 mRNA levels in mouse embryos at E 9.5 with a pair of primers covering unaltered exon 1 region showed that embryos express around fourfold more compared to equivalent ES cells (Fig. 2c) . Similarly to ES cells, a decrease of Rheb1 mRNA was also identified in Rheb1 +/ − embryos when the used primers were related to deleted exon 8 (Fig. 2d) . No Rheb1 mRNA was detected in Rheb1 −/− embryos. This confirmed that homozygous
Rheb1 disruption lead to complete inactivation of the gene. The level of RHEB1 protein was tested in MEFs of different genotypes by Western blotting (Fig. 3a, b ). The amount of RHEB1 was decreased (approximately twofold) in lysates of Rheb1 +/− MEFs. Some (nonsignificant) decrease was also identified in Rheb1 Δ/Δ or Rheb1 Δ/+ MEFs compared with wild-type MEFs (Fig. 3c,   d ). Thus, analysis of the expression of mRNA and protein in Rheb1 mutant embryos showed that Rheb1 was knocked out by conventional gene targeting but it was not inactivated completely by the gene trap approach. Rheb1is highly expressed in the brain of embryos and young mice (Tian et al. 2016) . It was interesting to learn how its expression in the brain of wild type and Rheb1 mutant mice changes with age. The protein level of RHEB1 in the brain of wild-type mice slightly decreased with age between 1 month and 2 years, but it was not statistically significant ( Fig. 3e, f) . The Rheb1 +/− and Rheb1 Δ /− mice showed double RHEB1 reduction in the brain compared with wild-type mice of the same age. Similarly to wild-type mice, small age-related reduction (non-significant) of RHEB1 protein levels were identified in total brain lysates of the Rheb1 +/− and Rheb1
Behavior of Rheb1 mutant mice
Mice of both Rheb1 mutant lines were monitored for more than 2 years. Young females and males separated by gender after weaning were maintained as three to four Furthermore, there were no obvious differences in the behavior of Rheb1 mutant mice and the behavior of control mice when both test and stimulus animals were wild-type B6N mice (data not shown). After SI testing, the mice were kept up to 1 year as breeding pairs with different combinations of Rheb1-mutant alleles. No obvious behavioral changes were detected when the mice were cared for in the breeding cages.
Neurological abnormality of Rheb1 mutant mice Breeding pairs were separated at the age of 1 year, and several females and males of every genotype were singly housed in cages for an additional year. The mice of either sex with different combinations of Rheb1 wildtype and/or mutant alleles showed no neurological disorders up to the age of 18 months. However, upon opening cages, some Rheb1mutant mice at around the age of around 18 months showed abnormal reactions that appeared to resemble stress-induced seizures. We found that only Rheb1 +/− and Rheb1 Δ/− males had the seizure-like neurological abnormality (Table 1) . Moderate seizures were induced by cage opening and/or transfer of mouse into new cages and reached stage 1-2 according the Racine scale (Fig. 4a, b) . Since reactions of mice with these two manipulations did not show significant differences, they were combined and labeled as the reactions on cage opening. Even though all Rheb1 +/− and Rheb1 Δ/− males repeatedly manifested the convulsions during a period of observation, seizures were not detected consistently every week. The frequency of convulsion events upon opening the cage was 0.59 ± 0.16 and 0.66 ± 0.50 mouse/week for Rheb1
and Rheb1 Δ/− males, respectively. If a mouse did not manifest convulsions, it was given a score of 0. Mean 
, ♂ 4 (4) 0.59 ± 0.16 1.00 ± 0.86 0.84 ± 0.50 2.63 ± 1.36
, ♂ 4 (4) 0.66 ± 0.5 0.88 ± 0.75 0.92 ± 0.70 2.94 ± 1.19
Mice were regularly observed weekly during 8 weeks. The seizure manifestations were recorded upon opening the cage and after being placed in an open space. Frequency of seizure events were counted as number of weeks when an individual mouse manifested seizures divided on 8 weeks of observation, and then the mean and standard deviation was calculated for each group of four mice of the same sex and genotype. Seizure severity scores on the Racine scale were averaged for each individual mouse manifested over the 8 weeks, and then the mean and standard deviation was calculated for four mice with the same sex and genotype. The seizures were identified in Rheb1 +/− and Rheb1 Δ/− males only. All Rheb1 +/− and Rheb1 Δ/− males manifested seizures at some point; however, they were not detected every week. Monitoring of the main mouse group ended at 24 months. Three female mice (two Rheb1 +/− and one Rheb1 Δ/− ) were monitored for two additional months; no seizures were observed convulsion stages were scored as 1.00 ± 0.86 and 0.88 ± 0.75 for Moreover, the mice manifested even more severe seizures. Behavior was often characterized by aberrant tail position (Fig. 4c) , resembling Straub tail (Bilbey et al. 1960 ) that occurs as a sensitive biological reaction to morphine. Furthermore, seizures could sometimes reach stage 4, which is characterized by clonic convulsions (Fig. 4d) . Convulsion achieved 2.63 ± 1.36 and 2.94 ± 1.19 for Rheb1 +/− and Rheb1 Δ/− males, respectively. These evoked seizures of Rheb1-insufficient males lasted an average of 35 ± 13 s and thereafter, the mice recovered; none died. Males and females of other Rheb1 mutant genotypes, including Rheb1 +/− and Rheb1
Δ/− females, demonstrated normal behavior without any neurological abnormalities (Fig. 4e, f) . Furthermore, since RHEB1 is highly expressed in the cerebellum, we suggested that its double and long-term reduction can potentially lead to ataxia. However, we did not observe any visible symptoms of ataxia such as loss of equilibrium, body sway, tremor, or other manifestations.
Discussion
To investigate a potential effect of prolonged reduction of RHEB1 on the behavioral and on the functionality of the brain, we targeted the Rheb1 gene by two different methods. The mice produced by conventional targeting of exon 8 of Rheb1 have a similar phenotype, including double reduction of RHEB1 in Rheb1 +/− mice and embryonic lethality of Rheb1 −/− embryos, as other Rheb1 knockout mice described previously (Goorden et al. 2011) . In our second model, we targeted Rheb1 by gene trap method (Tian et al. 2016) . We showed that a pT1βgeo gene trap vector inserted within intron 1 of Rheb1 and B-GAL accurately reflected the promotor activity of the Btrapped^gene. Initially, it was suggested that the Rheb1-βgeo allele must lead to the expression of a highly truncated fusion protein encoding only 17 amino acids of RHEB1 fused to β-GAL. However, to +/− mice. Comparison of the amount of RHEB1protein in total brain lysates of young versus old mice showed a slight (non-significant) age-related reduction of RHEB1 protein as in wild type as well as in RHEB1-insufficient mice. We did not compare RHEB1 expression levels in different brain regions; it is therefore not known whether the RHEB1 decrease is specific to certain brain regions or instead reflects a uniform decrease throughout the brain. It is possible that RHEB1 reduction in some region(s) of the brain below some critical level can initiate rare stress-induced seizures.
It is well known that a reduced function of TSC1 and TSC2 proteins in patients leads to hyperactivation of the RHEB1/mTOR pathway in the brain and results in severe morphological changes and serious neurological manifestations including autism and mental retardation in humans (Caban et al. 2017; Jeong and Wong 2016) . By analogy with patients, the mice with targeted Tsc1 or Tsc2 showed hyperactivation of the mTOR pathway, have serious behavioral, neurological abnormality and early post-natal mortality (Zeng et al. 2008 (Zeng et al. , 2011 Abs et al. 2013; Meikle et al. 2007; Goorden et al. 2007 ). On the other hand, it is unknown how a long-term RHEB1 insufficiency and related reduced activity of the mTORC1 pathway influences neuronal functions, cognition, and behavior. Our Rheb1 +/− and Rheb1 Δ /− mutant mice had an approximately twofold reduction of RHEB1in total lysates of the brain and its level did not change significantly with age. Since RHEB1 is highly expressed in the brain regions responsible for different cognitive functions such as learning, longterm and short-term memory, and social behavior etc., we suggested that such RHEB1 insufficiency during aging would lead to some neurological abnormality and/or visible changes in behavior. So, these mice were subjected to long-term monitoring. To exclude an unpredicted effect of insertion of the gene trap vector on the behavioral phenotype, the Rheb1 Δ/+ and Rheb1 Δ/ Δ mice were also subjected to monitoring although they expressed normal amounts of RHEB1. Routine observations and special social interaction tests did not identify any behavioral differences of any of our Rheb1-mutant mice compared to wild-type control animals. This is in agreement with recently published results of the group of Elgersma (Goorden et al. 2015) . They used several other behavior tests (Morris water maze, contextual fear conditioning and rotarod) and showed that even 75% reduction of RHEB1 and downstream mTORC1 signaling in the brain did not affect synaptic plasticity and hippocampus-dependent learning and memory of mice. Thus, our results and the data of Elgersma's group demonstrated that long-term reduced RHEB1 expression do not affect a social behavior and cognitive functions of RHEB1-insufficient mice. Further, since RHEB1 has significant expression in the brain, we monitored the Rheb1 mutant mice to detect any neurological disorders. In spite of RHEB1 being highly expressed in the cerebellum, its long-term twofold reduction and downregulation of members of mTORC1 pathway correspondingly do not cause any visible symptoms of ataxia. Surprisingly, we found that RHEB1 reduction initiated stress-induced seizures in 1.5-2-year-old mice. Interestingly, only old RHEB1-insufficient males were prone to seizures. It seems that during life span, the brain structure and its functions are affected by RHEB1 insufficiency in cooperation with some additional modulators such as the sex. Manifestation of this neurological disorder exclusively in old males can potentially arise due to many different factors. During development, mTOR drives growth and reproduction, while causing aging and age-related diseases later in life for review (Blagosklonny 2010) . The males of different species (including human) show shorter lifespan compared with females (for review, Yashin et al. 2010; Gowaty 2007; Clutton-Brock and Isvaran 2007) . It might be that the seizures of old RHEB1-insufficient males are somehow connected with the mTORC1 pathway and due to a faster process of aging in males versus females. Another potential cause is the fundamental difference in the genome between female and male mice, related to the X and Y sex chromosomes. Other factor(s) might be a difference of the male and female endocrine systems that interacts dynamically with the brain and behavior throughout life (Duarte-Guterman et al. 2015 ; Sanchis-Segura and Becker 2016). These differences might modulate the activity of mTORC1 or downstream members of the mTORC1 pathway in neuronal cells of old RHEB1-insufficient males.
The mTORC1 inhibitors everolimus and other rapalogs are specifically used against seizures in young and middle-aged TSC and epilepsy patients (Jeong and Wong 2016; Franz et al. 2016) . Moreover, everolimus is used in combination with other medications for the treatment of a wide spectrum of diseases (for review, Calimeri and Ferreri 2017; Pelletier et al. 2016; Blair et al. 2017) . Several papers reported about the usage of everolimus to treat different diseases in old patients (Donati et al. 2017; Furian et al. 2014; Wei and Lai 2015) . However, there are no reports published about long-term treatment of seizure-prone old patients or old experimental animals by mTORC1 inhibitors. RHEB1 insufficiency has a similar effect on the mTORC1 signaling pathway as rapamycin or other rapalogs and should protect against seizures in general. Instead of this positive effect, a long-term RHEB1 insufficiency in our old males initiated stress-induced seizures. In spite of the general success of everolimus application against TSC, some undesirable effects are known. Some TSC patients with medically refractory epilepsy exhibit exacerbated seizure frequency despite continuous treatment with everolimus and that requires that the treatment be discontinued (Krueger et al. 2010; Krueger et al. 2016) . Seizures in old RHEB1-insufficient mice suggest that an increase of convulsions in some patients after treatment by mTOR1 inhibitors are not side effects of such inhibitors, rather to the downregulation of RHEB1/ mTORC1 signaling below a normal level.
As far as we are aware, no direct evidence is yet published that demonstrates whether prolonged downregulation RHEB1/mTORC1 signaling is a cause of diseases of the nervous system (NS) in human. Nevertheless, its reduction may potentially be involved in development of cognitive and other NS diseases. For example, a loss of mTOR activity in peripheral lymphocytes has a positive correlation with the progression of Alzheimer's disease (Paccalin et al. 2006) . Furthermore, development of some NS diseases may potentially be connected with reduced activity of the RHEB1/ mTORC1 pathway in certain regions of the brain. For instance, it is suggested that prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia (SZ) patients can result from a hypoactivation of the RHEB1/mTOR-P70S6K pathway (see Maas et al. 2017 for review). Moreover, the neurons of substantia nigra of post-mortem brains of Parkinson's disease (PD) patients have increased expression of RTP801 protein, an inhibitor of mTORC1 activity, which is requisite for cell death in cellular PD models (Malagelada et al. 2006) . Similarly, mTORC1 activity is reduced in striatal tissues from Huntington's disease (HD) patients, as detected by reduced phosphorylation of ribosomal protein S6 (pS6) (Lee et al. 2015) .
In summary, our data provide further support that the morphological structure of the brain and its cognitive/ behavioral functions are more sensitive to upregulation of the RHEB1/mTORC1 pathway than its down-regulation. However, unexpected stress-induced seizures in old RHEB1-insufficient males suggest that long-term down-regulation of the RHEB1/mTORC1 pathway can have negative effects.
It is particularly important because the current rapid increase in the proportion of elderly people may lead to a significant increase of the fraction of patients with epilepsy and other neurological disorders. Although many elderly people develop seizures, provoked by acute illness, in many others, the seizures occur without any obvious precipitating cause (Brodie et al. 2009 ). Therefore, to better understand potential connection of chronic down-regulation of the RHEB1/mTORC1 with the manifestation of seizures and other NS disorders in older human, a quantitative analysis of RHEB1 expression and mTORC1 pathway activity must be performed in different regions of the brain of old Rheb1 mutant mice in future. Such an investigation is of particular interest because of evidence suggesting that the development of SZ, PD, and HD in patients result from down-regulation of RHEB1/mTORC1 in certain regions of the brain. Furthermore, the electroencephalogram and other electrophysiological approaches and patho-histological examination of old brain in details will help to identify a cause(s) of seizures. Moreover, we hope that such investigations will help to understand why old Rheb1 mutant male mice only develop stressinduced seizures.
Materials and methods

Construction of the targeting vector
Since activity of proteins in the RAS family depends on farnesylation of the carboxyl terminus (so-called CAAX motif), we targeted the last (8) exon of Rheb1 containing the CSVM motif, the functional homolog of CAAX in RAS. To generate the Rheb1 targeting vector, the pKO Scrambler vector V901 (Lexicon) was used as backbone. For positive selection, a 1.6-kb AscI fragment containing the neomycin (neo) resistance gene (V800 vector, Lexicon) was inserted into the AscI site of vector V901. For negative selection, a 2 kb Rsr II fragment containing the thymidine kinase (tk) gene was isolated from V830 vector (Lexicon) and inserted into the Rsr II site of V901 vector. Genomic DNA corresponding to the Rheb1 locus was isolated from a lambda phage library derived from 129/Sv mouse DNA. A 5.8-kb Bgl II-Kpn I fragment containing exons 4-7 of Rheb1 (homology 1) was cloned into BglII-KpnI site. A 2.3-kb XhoI-XhoI fragment downstream of exon 8 (homology 2) was Klenovfill ended and inserted into a SmaI site of vector V901. The NotI-linearized Rheb1-targeting vector was electroporated into CJ7 ES cells of genetic background 129/Sv and G418 (geneticin) (200 μg/ml), and GANC (gancyclovir) (2 × 10 −6 M) was used for positive and negative selection correspondingly. Targeted clones were identified by Southern blot analysis according to standard protocol (Southern 1975 ) using a 3′ probe on BamHI-cut genomic DNA (Fig. 1a, b) . A 32 P-labeled PCR fragment spanning a region of 700 bp downstream of homology 2 region was used as probe for Southern blot hybridization. Integrity of genomic DNA was later confirmed through sequencing of a 550-bp fragment upstream of Rheb1 targeting vector.
Generation of Rheb1 haplo-insufficient mice Chimeric mice were created by injecting Rheb1-targeted ES cell clones into C57BL/6J (B6J) blastocysts according to standard protocol (Fedorov et al. 1997) . After germline transmission (GLT), the Rheb1-targeted allele was transferred to a C57BL/6N (B6N) background (Charles River Lab; more than 10 backcrosses).
Rheb1
Δ/+ mutant mice were produced early and maintained on B6N genetic background (Tian et al. 2016) . All mouse studies were performed in accordance with the guidelines established by the Institutional Animal Care and Use Committees of Oregon Health and Science University (Portland, OR, USA) and University of Jena (Germany). All mice were housed under SPF conditions, handled and sacrificed in accordance with institutional guidelines.
PCR genotyping
Live-born animals were screened for the presence of mutant Rheb1 in tail DNA using Southern blotting and/ or PCR. Preparation of tissues from adult mice and PCR were done using standard methods. The forward (F) primer 5′-CAGCCCACGTAATGAAGTGC-3′ and reverse (R) primer 5′-TTGTGCCTCCTGTA GCTCAG-3′ produce a 400-bp fragment-covered junction of exon 8 and post-exon 8 region of the wild-type Rheb1 allele, whereas a combination of N-primer 5′-GCATGCTCCAGACTGCCTTG-3′ (PGK-promoter of neo gene) with the same reverse (R) primer amplified a 200-bp fragment of the targeted allele of Rheb1 using the following PCR protocol: 94°C for 5 min followed by 35 cycles: 1 min at 94°C, 1 min at 54°C, and 30 s at 72°C. Embryonic tissues for PCR were prepared as described earlier ).
Genotyping of Rheb1
Δ/+ gene trap mice were done as described earlier (Tian et al. 2016) . Presence of the pT1βgeo vector was identified with primers corresponding to the β-galactosidase gene: forward primer 5′-GCG TTG GCA ATT TAA CCG CC-3′ and reverse primer 5′-CAG TTT ACC CGC TCT GCT AC-3′. The resulting PCR product was 450 bp. To genotype the wild-type Rheb1 and Rheb1 Δ alleles, the following additional pairs of primers were used. The sense primer RhebF1235 5′-CCT AGA CTG GAC CCC TCA CA-3′ and antisense primer RhebR1620 5′-ACG TGA CAG TCC CCT GTT CC-3′ were used to amplify a 385-bp fragment of wild-type allele, whereas a combination of the same sense RhebF1235 primer and mR4 5′-TGT GGG AAA GCC TTC AAA GGG-3′ amplifies a 238-bp fragment of the Rheb1 Δ allele. PCR was performed using the following protocol: 95°C for 5 min followed by 35 cycles: 45 s at 95°C, 45 s at 58°C and 1 min at 72°C followed by 6 min extension at 72°C.
Embryo generation
Staged embryos were produced by mating between wild-type, Rheb1
, and or Rheb1 Δ/+ (Rheb1 GT) mice.
Embryo isolation and organ identification were performed according to Kaufmann (2003) . The histopathological evaluation of mice including both gross and microscopic examination was performed as described recently (Tian et al. 2016) . The embryos at E13.5 were used for the preparation of mouse embryonic fibroblasts (MEFs). Individual embryos were isolated, trypsinized, passaged into 50-mmdiameter dish, and cultured in DMEM containing 10% fetal bovine serum. After formation of a confluent monolayer, MEFs from each dish were genotyped and 1.5 × 10 6 of cells were used for Western blotting.
Quantitative RT-PCR
RNA from the tissues of wild-type mice was prepared and reverse-transcribed as described above and treated with DNase. 'ing SYBR Green I reagent and pairs of primers related to Ex2-Ex5, Ex7-Ex8, and pairs of primers for single Ex1 or Ex8 of Rheb1 (Supplemental Table 1 ). Transcript-specific primers for β-actin as an endogenous control were used to evaluate the Rheb1 mRNA level. The 2-ddCT relative quantification method was used to calculate fold difference in transcript levels between samples (Livak and Schmittgen 2001) . Amplification efficiencies for the primer pairs were verified to be equivalent over a range of template concentrations. qRT-PCR was performed using an Applied Biosystems 7300 Real-Time PCR thermocycler (Applied Biosystems, Foster City, CA).
Western blot analysis MEF cells and brain tissues from euthanized mice were frozen in liquid nitrogen. Tissue lysates were prepared as described elsewhere (Fedorov et al. 2006 ). Proteins were detected by anti-RHEB1 mab (Abnova; no. H00006009-M01) diluted 1:500 and anti β-ACTIN mab (Cell Signaling, no. 8H10D10) diluted 1:5000. Secondary goat anti-mouse antibody conjugated to HRP (Bio-Rad, no. 1721011) was diluted at 1:10,000. The signal was detected using a chemiluminescence kit (PerkinElmer, Wellesley, MA). The intensity of the immunoblot bands was quantified by densitometric scanning with ImageJ analysis software (NIH) and normalized to β-actin (https://imagej.nih.gov/ij/).
SI tests
To test a possible behavior changes of the Rheb1 mutant mice 3-4 months old, Rheb1 +/− and Rheb1 Δ /− males and females were divided in four groups (three mice/group) according the genotype and sex. Behavior of Rheb1 mutant mice was evaluated as the interaction between individual male and female by social interaction test as described elsewhere (Panksepp et al. 2007) .Two approaches to testing the interaction were used: (a) a Rheb1 mutant male test mouse was placed with a normal B6N female stimulus mouse and (b) a Rheb1 mutant female test mouse was placed with a normal B6N male stimulus mouse. Interactions between normal individual B6N males and females were used as appropriate controls. Each Rheb1 mutant mouse (designated the Btest^mouse) was isolated for 24 h within a clean cage that contained fresh cellulose pellet bedding without nesting material. After 24 h, the B6N mouse designated the Bstimulus^mouse was added to the cage of the test mouse and the amount of social investigation that test mouse directed towards the stimulus mouse during a 5-min period was monitored. The variables of social investigation recorded included sniffing or snout contact with the head/neck/mouth area (1), direct contact with the anogenital area (2), and social pursuit within one body-length as the stimulus mouse moved continuously throughout the cage (3), and social grooming (4). All behaviors were videotaped (Sony, DCR-VX2100, Japan) and stored on a Dell Pentium IV PC for additional analysis. All behaviors were scored for composite duration and analyzed by software (ButtonBox v.5.0, Behavioral Research Solutions, Madison, WI, USA).
Analysis of induced seizures
To identify possible neurological abnormalities after genetic disruption of Rheb1, the mice were observed for two full years. After initially identifying seizures, the mice were regularly monitored to analyze and quantify the convulsions once per week for 8 weeks. The cages were opened and the reactions of the individual mice were recorded. Next, each mouse was gently picked up by the tail and transferred to the surface of an open platform (open space). Severity of seizures was quantified using a modified Racine scale (Harai et al. 2012; Racine 1972) , (0 = no response, 1 = mouth and facial jerks, 2 = convulsive waves axially through the body and/or Straub tail, 3 = forelimb clonus, 4 = rearing, falling down, hindlimb and forelimb clonus; 5 = generalized convulsions with a tonic extension episode and status epilepticus). Frequencies of seizure events and their severity were recorded and summarized separately for the opening of the cage and for the relocation of mice to the open space. During the period of regular observation, handling of mice and scoring of seizures were done by the same investigators. To validate and confirm a seizure phenotype, the convulsions where recorded on photo or video camera.
Statistical analysis
Statistical analysis was performed by Student t test using a P value of < 0.05 as statistically significant.
